177 related articles for article (PubMed ID: 24213953)
1. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Dahhan T; Balkenende E; van Wely M; Linn S; Goddijn M
Cochrane Database Syst Rev; 2013 Nov; (11):CD010240. PubMed ID: 24213953
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
4. Fertility preservation in women with breast cancer.
Rodriguez-Wallberg KA; Oktay K
Clin Obstet Gynecol; 2010 Dec; 53(4):753-62. PubMed ID: 21048442
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
6. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Dahhan T; Balkenende EME; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; van Golde RJT; Schipper I; Louwé LA; Cantineau AEP; Smeenk JMJ; de Bruin JP; Reddy N; Kopeika Y; van der Veen F; van Wely M; Linn SC; Goddijn M
Contemp Clin Trials; 2017 Oct; 61():96-100. PubMed ID: 28710053
[TBL] [Abstract][Full Text] [Related]
8. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?
Revelli A; Porcu E; Levi Setti PE; Delle Piane L; Merlo DF; Anserini P
Gynecol Endocrinol; 2013 Nov; 29(11):993-6. PubMed ID: 24000936
[TBL] [Abstract][Full Text] [Related]
9. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
Letourneau J; Juarez-Hernandez F; Wald K; Ribeiro S; Wang A; McCulloch CE; Mok-Lin E; Dolezal M; Chien AJ; Cedars MI; Rosen M
J Assist Reprod Genet; 2021 Sep; 38(9):2455-2463. PubMed ID: 34312774
[TBL] [Abstract][Full Text] [Related]
10. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
13. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
14. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
15. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome.
D'Angelo A; Amso N
Cochrane Database Syst Rev; 2002; (2):CD002806. PubMed ID: 12076453
[TBL] [Abstract][Full Text] [Related]
16. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
17. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Karnon J; Delea T; Johnston SR; Smith R; Brandman J; Sung J; Goss PE
Pharmacoeconomics; 2006; 24(3):237-50. PubMed ID: 16519546
[TBL] [Abstract][Full Text] [Related]
19. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
Oktay K; Buyuk E; Libertella N; Akar M; Rosenwaks Z
J Clin Oncol; 2005 Jul; 23(19):4347-53. PubMed ID: 15824416
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
